R
Raffaella Origa
Researcher at University of Cagliari
Publications - 98
Citations - 3993
Raffaella Origa is an academic researcher from University of Cagliari. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 25, co-authored 85 publications receiving 3406 citations.
Papers
More filters
Journal ArticleDOI
Beta-thalassemia
Renzo Galanello,Raffaella Origa +1 more
TL;DR: A group of hereditary blood disorders characterized by anomalies in the synthesis of the beta chains of hemoglobin resulting in variable phenotypes ranging from severe anemia to clinically asymptomatic individuals.
Journal ArticleDOI
Survival and complications in thalassemia.
Caterina Borgna-Pignatti,Maria Domenica Cappellini,P. De Stefano,G. C. Del Vecchio,Gian Luca Forni,Maria Rita Gamberini,R. Ghilardi,Raffaella Origa,Antonio Piga,Maria Antonietta Romeo,Huaqing Zhao,Avital Cnaan +11 more
TL;DR: In conclusion, rates of survival and complication‐free survival continue to improve, due to better treatment strategies, and new complications are appearing in long‐term survivors.
Journal ArticleDOI
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Raffaella Origa,Renzo Galanello,Tomas Ganz,Nicolina Giagu,L Maccioni,Gavino Faa,Elizabeta Nemeth +6 more
TL;DR: In thalassemia intermedia, high erythropoietic drive causes severe hepcidin deficiency, which results in hyperabsorption of dietary iron, but also in iron depletion of macrophages, lowering their secretion of ferritin and, consequently, serumferritin levels.
Journal ArticleDOI
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Antonio Piga,Renzo Galanello,Gian Luca Forni,Maria Domenica Cappellini,Raffaella Origa,Antonietta Zappu,Guido Donato,Elena Bordone,Antonella Lavagetto,Laura Zanaboni,Romain Sechaud,Nicola Hewson,John Ford,Herbert Opitz,Daniele Alberti +14 more
TL;DR: Deferasirox showed a plasma elimination half-life of 8-16 hours, supporting its once-daily administration, and was well tolerated and showed similar efficacy to DFO 40 mg/kg in terms of decreases in LIC.
Journal ArticleDOI
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
Sarah Marktel,Samantha Scaramuzza,Maria Pia Cicalese,Fabio Giglio,Stefania Galimberti,Maria Rosa Lidonnici,Valeria Calbi,Andrea Assanelli,Maria Ester Bernardo,Claudia Rossi,Andrea Calabria,Raffaella Milani,Salvatore Gattillo,Fabrizio Benedicenti,Giulio Spinozzi,Annamaria Aprile,Alessandra Bergami,Miriam Casiraghi,Giulia Consiglieri,Nicoletta Masera,Emanuela D'Angelo,Nadia Mirra,Raffaella Origa,Immacolata Tartaglione,Silverio Perrotta,Robert Winter,Milena Coppola,Gianluca Viarengo,Luca Santoleri,Giovanna Graziadei,Michela Gabaldo,Maria Grazia Valsecchi,Eugenio Montini,Luigi Naldini,Maria Domenica Cappellini,Fabio Ciceri,Alessandro Aiuti,Giuliana Ferrari +37 more
TL;DR: In a phase 1/2 clinical trial, gene therapy with autologous hematopoietic stem cells significantly reduced transfusion requirement in adults and children with transfusion dependent ß-thalassemia.